BioSpace News Archive

Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced that it is hosting a key opinion leader (KOL) call on a novel mechanism for the treatment of glaucoma on Friday, June 12, 2020 at 11:30am Eastern Time. The call will feature presentations by Dr. Paul Kaufman M.D. (University of Wisconsin) and

TruLife Distribution continues their streak of successful attendance at ECRM’s unprecedented all-virtual conference. With strong connections to many of the leading retail markets in the United States,

HistoSonics, developer of a non-invasive robotic platform and sonic beam therapy, announced today that it has closed $40 million in an oversubscribed Series C-1 financing. The round was led by Yonj

Nuvaira , a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira® Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (

Echosens , a high-technology company offering the FibroScan family of products, joins healthcare leaders worldwide in recognition of International NASH Day , June 12, 2020, a series of virtual events via a global social media campaign, to increase awareness about non-alcoholic steatohepatitis (NASH) among the general public, at-risk patients, the medical community, public health authorities and the media. T

Dendreon Pharmaceuticals, a commercial-stage biopharmaceutical company and pioneer in the development of immunotherapy, today announced the appointment of Jason O’Neill as chief executive officer, effective June 1, 2020. O’Neill brings extensive pharmaceutical leadership experience to Dendreon, with prominent roles in the are

Rite Aid named top traditional drug store chain in US for removing harmful chemicals in products sold

Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced European Spine Journal publication of long-term data from the Level I SMART trial showing durability of improvements in pain and function beyond 5 years for patients treated with the Intracept procedure. The recently published long-term study i is a single-arm, open-label, prospective follow-up of 100 US pati

Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating, diversified life sciences Company, with a proprietary line of functional “supplement” chewing gums (versions: infused with CBD, CBG, Vitamin C & Zinc) and edibles product(s) as well as two ongoing Biotechnology initiatives, today announced that it is taking concrete steps to expand into the fast growing Cannabidiol (“CBD”) infused pet food(s) market segment.

Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received Chinese regulatory approval for the Edwards SAPIEN 3 transcatheter heart valve for the treatment of patients suffering from severe, symptomatic aortic stenosis (AS) at high risk for or unable to undergo open-heart surgery.